Exploring Nonmonotonic Associations Between Cannabis Use and Alcohol
This article examines nonmonotonic cannabis alcohol use frequency associations and their implications for clinical practice. Understanding these patterns helps clinicians monitor patient outcomes more effectively. Nonmonotonic cannabis alcohol use…
Can Cannabis Replace Opioids for Chronic Pain? What We Know and What Remains Uncertain
This 2025 narrative review explores cannabinoid analgesia mechanisms and their role in chronic pain management. It highlights biological plausibility and clinical evidence supporting cannabinoids for neuropathic and arthritis pain. However, significant…
CBD’s Promise Outpaces Its Proof: A Comprehensive Review Finds Most Cannabis Products Lack Regulatory-Grade Evidence
CBD therapeutic development is advancing but regulatory-grade evidence remains limited. Most cannabis products lack robust clinical support beyond rare epilepsy syndromes. This review highlights the urgent need for rigorous trials and quality standards.
Cannabis Stocks To Research – March 26th | MarketBeat
This article covers cannabis stocks research March 26th MarketBeat with a focus on clinical evidence and patient safety. It highlights the distinction between financial market trends and medical cannabis treatment. Clinicians should rely on clinical data…
Unraveling Lennox-Gastaut Syndrome: Molecular Pathogenesis and Therapeutic Strategies
Lennox-Gastaut syndrome treatment challenges arise from its complex network dysfunction and drug-resistant seizures. Precision medicine approaches targeting molecular pathways offer new hope. CBD has shown efficacy as adjunctive therapy for this severe…
Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.
This review addresses cannabinoid therapies rare diseases by examining clinical evidence for less-common disorders. It highlights formulation strategies tailored to individual patient needs. The article provides a framework for clinicians considering…
Medical Cannabis and Epilepsy: Reviewing the Evidence
Cannabis epilepsy treatment evidence highlights the anticonvulsant properties of CBD and THC in managing seizures. Approximately 30% of epilepsy patients have drug-resistant forms that may benefit from cannabis-based therapies. Understanding this…
Senate Bill Broadens Cannabis Access in Georgia: Clinical Insights
Georgia cannabis access expansion is clinically significant for evidence-based medicine. This legislation broadens product availability but raises concerns about dosing and safety. Clinicians should monitor these changes closely for patient guidance.
Many Industry Standards Stem from Bom Group’s Innovations
Bom Group's cannabis manufacturing quality control innovations have significantly influenced industry standards. These standards improve product consistency and safety across the legal cannabis market. Understanding these innovations helps clinicians and…
Indiana Governor Signals Potential Shift on Marijuana Legalization
Indiana medical cannabis program challenges are gaining attention as the governor signals openness to legalization discussions. Clinicians should prepare for new clinical oversight and patient safety protocols. This evolving policy landscape impacts…
